In vitro antibacterial activity of meropenem

Masatomo Fukasawa, Yoshihiro Sumita, Eiko Tada, Takao Okuda

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The in vitro antibacterial activity of meropenem (MEPM), a new carbapenem antibiotic, was compared with those of imipenem (IPM), cefazolin, cefotiam, ceftazidime (CAZ), cefotaxime and latamoxef. MEPM was found to be a very broad spectrum antibacterial agent that was similar to IPM. Against clinical isolates of staphylococci, including methicillin-resistant Staphylococcus aureus, the MIC90 of MEPM ranged from 0.78 to 12.5 µg/ml. Its activity was inferior to that of IPM but superior to that of the cephalosporins tested. MIC90 values of MEPM against clinical isolates of Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Serratia marcescens, Proteus mirabilis, Proteus vulgaris and Pseudomonas aeruginosa were ≦0.003, ≦0.003, 0.025, 0.025, 0.025, 0.20, 0.10, 1.56, 0.20, 0.20 and 1.56 µg/ml, respectively. MEPM was 2- to 4-fold more active than IPM and CAZ against P. aeruginosa. It also showed potent activity against Haemophilus influenzae and Bacteroides fragilis. The antibacterial activity of MEPM was slightly affected by inoculum size, culture medium, pH of the medium and the addition of human serum. It showed bactericidal activity against a variety of bacteria.

Original languageEnglish
Pages (from-to)74-89
Number of pages16
JournalChemotherapy
Volume40
DOIs
Publication statusPublished - Jan 1 1992
Externally publishedYes

Fingerprint

meropenem
Imipenem
Ceftazidime
Pseudomonas aeruginosa
Cefotiam
Citrobacter freundii
Moxalactam
Proteus vulgaris
Enterobacter aerogenes
Enterobacter cloacae
Cefazolin
Bacteroides fragilis
Proteus mirabilis
Serratia marcescens
Carbapenems
Cefotaxime
Streptococcus pyogenes
Haemophilus influenzae
Klebsiella pneumoniae
Cephalosporins

Keywords

  • Meropenem

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Cite this

In vitro antibacterial activity of meropenem. / Fukasawa, Masatomo; Sumita, Yoshihiro; Tada, Eiko; Okuda, Takao.

In: Chemotherapy, Vol. 40, 01.01.1992, p. 74-89.

Research output: Contribution to journalArticle

Fukasawa, Masatomo ; Sumita, Yoshihiro ; Tada, Eiko ; Okuda, Takao. / In vitro antibacterial activity of meropenem. In: Chemotherapy. 1992 ; Vol. 40. pp. 74-89.
@article{2510a657e9e0432593ad48df6150a883,
title = "In vitro antibacterial activity of meropenem",
abstract = "The in vitro antibacterial activity of meropenem (MEPM), a new carbapenem antibiotic, was compared with those of imipenem (IPM), cefazolin, cefotiam, ceftazidime (CAZ), cefotaxime and latamoxef. MEPM was found to be a very broad spectrum antibacterial agent that was similar to IPM. Against clinical isolates of staphylococci, including methicillin-resistant Staphylococcus aureus, the MIC90 of MEPM ranged from 0.78 to 12.5 µg/ml. Its activity was inferior to that of IPM but superior to that of the cephalosporins tested. MIC90 values of MEPM against clinical isolates of Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Serratia marcescens, Proteus mirabilis, Proteus vulgaris and Pseudomonas aeruginosa were ≦0.003, ≦0.003, 0.025, 0.025, 0.025, 0.20, 0.10, 1.56, 0.20, 0.20 and 1.56 µg/ml, respectively. MEPM was 2- to 4-fold more active than IPM and CAZ against P. aeruginosa. It also showed potent activity against Haemophilus influenzae and Bacteroides fragilis. The antibacterial activity of MEPM was slightly affected by inoculum size, culture medium, pH of the medium and the addition of human serum. It showed bactericidal activity against a variety of bacteria.",
keywords = "Meropenem",
author = "Masatomo Fukasawa and Yoshihiro Sumita and Eiko Tada and Takao Okuda",
year = "1992",
month = "1",
day = "1",
doi = "10.11250/chemotherapy1953.40.Supplement1_74",
language = "English",
volume = "40",
pages = "74--89",
journal = "Chemotherapy",
issn = "0009-3165",

}

TY - JOUR

T1 - In vitro antibacterial activity of meropenem

AU - Fukasawa, Masatomo

AU - Sumita, Yoshihiro

AU - Tada, Eiko

AU - Okuda, Takao

PY - 1992/1/1

Y1 - 1992/1/1

N2 - The in vitro antibacterial activity of meropenem (MEPM), a new carbapenem antibiotic, was compared with those of imipenem (IPM), cefazolin, cefotiam, ceftazidime (CAZ), cefotaxime and latamoxef. MEPM was found to be a very broad spectrum antibacterial agent that was similar to IPM. Against clinical isolates of staphylococci, including methicillin-resistant Staphylococcus aureus, the MIC90 of MEPM ranged from 0.78 to 12.5 µg/ml. Its activity was inferior to that of IPM but superior to that of the cephalosporins tested. MIC90 values of MEPM against clinical isolates of Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Serratia marcescens, Proteus mirabilis, Proteus vulgaris and Pseudomonas aeruginosa were ≦0.003, ≦0.003, 0.025, 0.025, 0.025, 0.20, 0.10, 1.56, 0.20, 0.20 and 1.56 µg/ml, respectively. MEPM was 2- to 4-fold more active than IPM and CAZ against P. aeruginosa. It also showed potent activity against Haemophilus influenzae and Bacteroides fragilis. The antibacterial activity of MEPM was slightly affected by inoculum size, culture medium, pH of the medium and the addition of human serum. It showed bactericidal activity against a variety of bacteria.

AB - The in vitro antibacterial activity of meropenem (MEPM), a new carbapenem antibiotic, was compared with those of imipenem (IPM), cefazolin, cefotiam, ceftazidime (CAZ), cefotaxime and latamoxef. MEPM was found to be a very broad spectrum antibacterial agent that was similar to IPM. Against clinical isolates of staphylococci, including methicillin-resistant Staphylococcus aureus, the MIC90 of MEPM ranged from 0.78 to 12.5 µg/ml. Its activity was inferior to that of IPM but superior to that of the cephalosporins tested. MIC90 values of MEPM against clinical isolates of Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Serratia marcescens, Proteus mirabilis, Proteus vulgaris and Pseudomonas aeruginosa were ≦0.003, ≦0.003, 0.025, 0.025, 0.025, 0.20, 0.10, 1.56, 0.20, 0.20 and 1.56 µg/ml, respectively. MEPM was 2- to 4-fold more active than IPM and CAZ against P. aeruginosa. It also showed potent activity against Haemophilus influenzae and Bacteroides fragilis. The antibacterial activity of MEPM was slightly affected by inoculum size, culture medium, pH of the medium and the addition of human serum. It showed bactericidal activity against a variety of bacteria.

KW - Meropenem

UR - http://www.scopus.com/inward/record.url?scp=0026694365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026694365&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.40.Supplement1_74

DO - 10.11250/chemotherapy1953.40.Supplement1_74

M3 - Article

VL - 40

SP - 74

EP - 89

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

ER -